An open-label, multicenter, phase II study to evaluate the therapeutic activity of ro6874281, an immunocytokine, consisting of interleukin-2 variant (il-2v) targeting fibroblast activation protein-? (fap), in combination with atezolizumab (anti-pd-l1), administered intravenously, in participants with advanced and/or metastatic solid tumors